Effect of highly active antiretroviral therapy on cardiovascular involvement in children with human immunodeficiency virus infection

Pediatric Infectious Disease Journal

Volumn 23, Issue 6, 2004, Pages 559-563

  Plebani, Anna ^a   Esposito, Susanna ^a   Pinzani, Raffaella ^a   Fesslova, Vlasta ^b   Bojanin, Jelena ^a   Salice, Patrizia ^b   Rossi, Matteo ^a   Principi, Nicola ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b Division of Cardiology   (Italy)

Author keywords

Antiretroviral therapy; Children; Heart; Highly active antiretroviral therapy; Human immunodeficiency virus infection

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; LOPINAVIR; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CARDIOVASCULAR SYSTEM; CHILD; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DRUG EFFECT; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; METABOLIC DISORDER; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGE DISTRIBUTION; ANALYSIS OF VARIANCE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; ITALY; LONGITUDINAL STUDIES; MALE; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION;

EID: 3042545918     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000130073.48745.a6     Document Type: Article

References (14)

1. Saulsbury FT. Resolution of organ-specific complications of human immunodeficiency virus infection in children with use of highly active antiretroviral therapy. Clin Infect Dis. 2001;32:464-468.
2. Viganò A, Vella S, Saresella M, et al. Early immune reconstitution after potent antiretroviral therapy in HIV-infected children correlates with the increase in thymus volume. AIDS. 2000;14:251-261.
3. Masur H, Kaplan JE, Holmes KK, United States Public Health Service, Infectious Disease Society of America. Guidelines for preventing opportunistic infections among HIV-infected persons: 2002. Recommendations of the U.S. Public Health Service and the Infectious Diseases Society of America. Ann Intern Med. 2002;137:435-478.
4. Hadigan C, Meigs JB, Wilson PWF, et al. Prediction of coronary heart disease risk in HIV-infected patients with fat redistribution. Clin Infect Dis. 2003;36:909-916.
5. 2 HIV): a cohort study. Lancet. 2002;360:368-373.
6. Barbarini G, Barbaro G. Incidence of the involvement of the cardiovascular system in HIV infection. AIDS. 2003;17(Suppl. 1):S46-S50.
7. 2 HIV Study. J Pediatr. 2002;141:327-335.
8. 2 HIV Study. Circulation. 2001;104: 310-316.
9. Cupler EJ, Danon MC, Jay C, et al. Early features of zidovudine- associated myopathy: histopathological findings and clinical correlations. Acta Neuropathol. 1995;90:1-6.
10. Lamperth L, Dalakas MC, Dagani F, et al. Abnormal skeletal and cardiac muscle mitochondria induced by zidovudine (AZT) in human muscle in vitro and in an animal model. Lab Invest. 1991;65:742-751.
11. Lipschultz SE, Orav EJ, Sanders SP, et al. Cardiac structure and function in children with human immunodeficiency virus infection treated with zidovudine. N Engl J Med. 1992;327:1260-1265.
12. Lipschultz SE, Easley KA, Orav EJ, et al. Absence of cardiac toxicity of zidovudine in infants. N Engl J Med. 2000;343:759-805.
13. Friis-Møller N, Weber R, Reiss P, et al. Cardiovascular disease risk factors in HIV patients: association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17:1179-1193.
14. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med. 2003;348:702-710.